High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Jean‐Paul Fermand(Sorbonne Université), Pierre Ronco(Inserm), Bruno Lioure, J. Jaubert(Institute Cancer De La Loire Lucien Neuwirth), Fabrice Quet(Centre National pour la Recherche Scientifique et Technique (CNRST)), Xavier Leleu(Inserm), Michel Cogné(Centre National de la Recherche Scientifique), Olivier Hermine(Centre National de la Recherche Scientifique), Lotfi Benboubker, Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Fabrice Jardin(Laboratoire National Henri Becquerel), Bouchra Asli(Hôpital Saint-Louis), Frank Bridoux(Université de Poitiers), Philippe Moreau(Centre National de la Recherche Scientifique), B. Grosbois(Centre Hospitalier Universitaire de Rennes), Jean‐Charles Piette(Sorbonne Université), Véronique Leblond(Sorbonne Université), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 520
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k